GlaxoSmithKline Signs US$3 B Synthetic Lethality Alliance with IDEAYA Biosciences
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)
Published: 30 Jun-2020
DOI: 10.3833/pdr.v2020.i6.2546 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Highlighting its continued focus in oncology, GlaxoSmithKline (GSK) has agreed to partner with IDEAYA Biosciences for its synthetic lethality programmes targeting MAT2A, Pol Theta, and Werner Helicase...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS